United Non Current Liabilities Total from 2010 to 2024
| UTHR Stock | USD 275.13 4.68 1.73% |
Non Current Liabilities Total | First Reported 1999-03-31 | Previous Quarter 377.8 M | Current Value 296.5 M | Quarterly Volatility 320.8 M |
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many exotic indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
United | Non Current Liabilities Total |
Latest United Therapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of United Therapeutics over the last few years. It is United Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
United Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 390,035,687 | |
| Geometric Mean | 196,929,989 | |
| Coefficient Of Variation | 79.18 | |
| Mean Deviation | 242,100,967 | |
| Median | 316,600,000 | |
| Standard Deviation | 308,819,664 | |
| Sample Variance | 95369.6T | |
| Range | 904.6M | |
| R-Value | 0.60 | |
| Mean Square Error | 65881.9T | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 41,348,261 | |
| Total Sum of Squares | 1335174.2T |
United Non Current Liabilities Total History
About United Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include United Therapeutics income statement, its balance sheet, and the statement of cash flows. United Therapeutics investors use historical funamental indicators, such as United Therapeutics's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may use each financial statement separately, they are all related. The changes in United Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on United Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on United Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 377.8 M | 269.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of United Therapeutics Correlation against competitors. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.27 | Earnings Share 21.15 | Revenue Per Share 53.184 | Quarterly Revenue Growth 0.337 | Return On Assets 0.1225 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.